Cancer survival linked to cardiovascular hormone/peptide levels
the ONA take:
Cardiovascular biomarkers such as high circulating levels of cardiovascular hormones/peptides in patients with cancer are linked to shorter survival, according to research published online in Heart.
In this study, researchers sought to determine whether the cancer itself affects levels of cardiovascular hormones/peptides.
The researchers assessed circulating levels of several cardiovascular hormones; proteins indicative of inflammation; and high sensitive troponin (hsTNT), a chemical that regulates heart muscle contractions, in 555 people with a first cancer diagnosis.
None of the participants had yet undergone any drug or radiotherapy treatments that might have damaged their heart tissue. The participants were tracked for an average of 25 months.
Almost one-third of the participants died during the monitoring period. Analysis of their blood samples showed that all the hormones measured and hsTNT increased in tandem with disease severity, sometimes to levels 100 times higher than expected.
The researchers report that their findings suggest that these biomarkers were indicative of heart damage not yet clinically evident, but directly linked to the cancer progression.
Furthermore, the findings suggest that the benefits of heart failure drugs for cancer patients may extend beyond helping to reduce cardiovascular side effects of cancer treatment.
Cardiovascular biomarkers such as high circulating levels of cardiovascular hormones/peptides in cancer are linked to shorter survival.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|